Tag: Gilboa
Gilboa Therapeutics Presents Pre-clinical Data at AACR Supporting SolidT Engineered T-Cell Platform Targeting Solid Tumors
Gilboa will present in vitro and in vivo data at the AACR Annual Meeting demonstrating non-clinical proof of concept for SolidT cells co-administered with therapeutic antibodies. Cambridge, MA, USA – WEBWIRE – Tuesday, April 9, 2024 Gilboa Therapeutics, a preclinical stage biotechnology company, today announced the presentation of pre-clinical data at the annual meeting of the American Association for Cancer Research demonstrating that its novel T-cell therapy platform, SolidT, has the potential to reprogram T cells to detect and destroy solid tumor cells while leaving normal cells unharmed, and establish immune memory to eliminate secondary tumors. The presentation is entitled ... Read more